Mitral valve repair for ischemic moderate mitral regurgitation in patients undergoing coronary artery bypass grafting

FARUK TOKTAS, MD, SENOL YAVUZ, MD, KADIR K. OZSIN, MD, UMIT S. SANRI, MD.

ABSTRACT

Objectives: To investigate whether mitral valve repair (MVR) at the time of coronary artery bypass grafting (CABG) in patients with ischemic moderate mitral regurgitation (MR) and coronary artery disease could improve short- and mid-term postoperative outcomes.

Methods: Between March 2013 and December 2015, 90 patients with moderate ischemic MR underwent first-time CABG in Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey. Out of 90 patients, 44 (48.9%) underwent combined CABG+MVR. The remaining 46 (51.1%) underwent CABG alone. Ventricular functions and effort capacities of patients in both groups were evaluated echocardiographically and clinically in the preoperative period, and in the first postoperative year.

Results: Postoperative regurgitant volume changes according to preoperative values were -24.76±19 ml/beat in the combined CABG+MVR group, and -8.70±7.2 ml/beat in the CABG alone group (p=0.001). The change of vena contracta width was -3.40±0.2 mm in the combined CABG+MVR group whereas in the CABG alone group, +1.45±0.7 mm (p=0.019). The changes of left ventricular end-systolic volume index were -30.77±25.9 ml/m² in the combined CABG+MVR group and +15.6±9.4 ml/m² in the CABG alone group (p=0.096). Ejection fraction changes in the combined CABG+MVR group was +1.51±5.3% and in the CABG alone group was +1.15±4.3%. No statistically significant difference was found between both groups (p=0.604). Preoperative New York Heart Association class values in the combined CABG+MVR group was 2.18±0.45, and in the CABG alone group was 2.13±0.54.

Conclusions: Moderate MR in patients undergoing CABG affects the outcome adversely and it does not reliably improve after CABG alone. Therefore, patients with ischemic moderate MR should undergo simultaneous MVR at the time of CABG.
Functional ischemic mitral regurgitation (MR) emerges in almost half of patients with myocardial infarction. Such exposure may vary from mild MR to severe MR, which may lead to severe heart failure and death. Diastemal and geometrical changes of the myocardium, depending on having myocardial infarction and coronary artery disease, and ischemia-affected chorda and papillary muscles make up the major cause of MR. When MR in patients undergoing coronary artery bypass grafting (CABG) is severe, surgical intervention of the mitral valve is mandatory. However, the role of intervening mitral valve of the patients with moderate MR who will undergo coronary bypass surgery, has been not agreed upon exactly due to the extra surgical process. Some surgeons think that moderate MR also improves if they can correct the ischemia with CABG. Surgeons are more reluctant to perform mitral valve interventions, as they worry that mitral valve surgery together with coronary revascularization can increase the morbidity and mortality rate. The aim of this study was to investigate whether MVR at the time of CABG in patients with ischemic moderate MR and coronary artery disease could improve short- and mid-term postoperative outcomes.

**Methods.** Ninety patients with moderate ischemic MR underwent first-time CABG in Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey, between March 2013 and December 2015. Out of the 90 patients, 44 (48.9%) underwent combined CABG + mitral valve repair (MVR). The remaining 46 (51.1%) underwent CABG alone (Table 1). During operation, the decision regarding MVR was at the surgeons’ discretion. The Institutional Ethics Committee approved this retrospective study, and the patients written consent was received. In this study, exclusion criteria were as follows: serious left ventricular dysfunction (ejection fraction [EF] <25%), coexisting serious aortic valve disease, the existence of active endocarditis, history of any cardiac operation, experiencing emergencies such as pulmonary edema and cardiogenic shock, and serious organ dysfunction (renal failure, severe chronic obstructive pulmonary disease, liver failure). Ventricular functions and effort capacities of the patients in both groups were evaluated by echocardiographic study and clinical examination.

**Table 1 -** Preoperative characteristics and demographic data of 90 patients with moderate ischemic mitral regurgitation undergoing CABG in Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey.

| Demographic data                      | Combined CABG+MVR (n=44) | CABG alone (n=46) | P-value |
|---------------------------------------|--------------------------|-------------------|---------|
| Age (mean±SD)                         | 61±5.2                   | 63±2.7            | 0.8     |
| Gender (female/male)                  | 21/23                    | 19/27             | 0.7     |
| Body mass index (meant±SD)            | 28±5.0                   | 29±3.1            | 0.7     |
| COPD                                  | 6 (13.6)                 | 8 (17.0)          | 0.3     |
| Diabetes mellitus                     | 26 (59.0)                | 27 (58.6)         | 0.7     |
| Previous cerebrovascular accident     | 1 (2.2)                  | 2 (4.3)           | 0.2     |
| Peripheral artery disease             | 7 (15.9)                 | 6 (13.0)          | 0.8     |
| Atrial fibrillation                   | 7 (15.9)                 | 8 (17.3)          | 0.3     |
| Tricuspid valve regurgitation (moderate to severe ) | 9 (20.4) | 8 (17.3) | 0.3 |
| Single-vessel coronary disease        | 3 (6.8)                  | 5 (10.8)          | 0.3     |
| Two-vessel coronary disease           | 7 (15.9)                 | 9 (19.5)          | 0.3     |
| Triple-vessel coronary disease        | 15 (34.0)                | 14 (30.4)         | 0.7     |
| Multi-vessel coronary disease         | 19 (43.1)                | 18 (39.1)         | 0.2     |

COPD - chronic obstructive pulmonary disease, CABG - coronary artery bypass grafting, MVR - mitral valve repair.

Echocardiographic parameters and effort capacities of both patient groups were evaluated both preoperatively and postoperatively at months 3 and 6, and in year one, whereas the patients who were followed up longer were evaluated every year. They were followed up on average for 17 months. The first-year measurements of these values were used in the study. Regurgitant volume, vena contracta, left ventricular end systolic volume index (LVESVI), and EF measurements of the combined CABG+MVR and CABG alone groups were compared echocardiographically. Mitral regurgitation was evaluated through echocardiography according to the criteria of moderate MR stated in the American Heart Association (AHA) and American Society of Echocardiography (ASE) guidelines. Patients who had effective MR area of 0.20-0.39 cm², regurgitant volume of 30-59 ml/beat, regurgitant fraction of 30-49%, and vena contracta width of 0.30-0.69 cm in this evaluation were included in the study group. Preoperative and postoperative effort capacities of the patients were evaluated according to the New York Heart Association (NYHA) functional classification (Table 2). Patients of both groups had similar optimal medical treatments in the postoperative period. Aspirin, beta blocker, angiotensin converting enzyme inhibitors (ACE), and statin were administered to all patients who had no contraindications. Warfarin was given to combined

**Disclosure.** Authors have no conflict of interests, and the work was not supported or funded by any drug company.
MVR for ischemic moderate MR … Toktas et al

Table 2 - New York Heart Association (NYHA) classes range from I to IV, with higher classes indicating poorer condition.

| NYHA class | Preoperative effort capacity | Postoperative effort capacity |
|------------|-----------------------------|------------------------------|
|            | Combined CABG+MVR n=44 | CABG alone n=46 | Combined CABG+MVR n=41 | CABG alone n=41 |
| Class I (%) | 3 (6.8) | 4 (8.7) | 12 (29.3) | 9 (22.0) |
| Class II (%) | 30 (68.2) | 32 (69.6) | 26 (34.4) | 25 (61.0) |
| Class III (%) | 11 (25.0) | 10 (21.7) | 3 (7.3) | 6 (14.6) |
| Class IV (%) | - | - | - | 1 (2.4) |
| Mean NYHA class (mean±SD) | 2.18±0.45 | 2.13±0.54 | 1.78±0.56* | 1.97±0.68** |

*p<0.002, **p<0.02

Table 3 - Operative and postoperative results of 90 patients with moderate ischemic mitral regurgitation undergoing CABG in Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey.

| Results | Combined CABG+MVR (n=44) | CABG alone (n=46) | P-value |
|---------|--------------------------|-------------------|---------|
| Coronary artery distal anastomosis | 3.0 | 3.1 | 0.7 |
| Tricuspid valve annuloplasty | 9 (20.4) | 8 (17.3) | 0.3 |
| Cross-clamp time (min) (mean±SD) | 92 ± 17 | 58 ± 22 | 0.002 |
| IABP use | 3 (6.8) | 2 (4.3) | 0.2 |
| Intubation time (hours) (mean±SD) | 17 ± 9 | 14 ± 5 | 0.2 |
| Hemodialysis need | 3 (6.8) | 3 (6.5) | 0.8 |
| 30-day mortality | 1 (2.2) | 1 (2.1) | - |
| Cerebrovascular accident | 1 (2.2) | - | - |
| Bleeding revision | 1 (2.2) | - | - |
| Triangular resection | 12 (27.2) | - | - |
| Commissuroplasty | 5 (11.3) | - | - |
| Neocorda implantation | 7 (15.9) | - | - |

Data are expressed as number (percentage). CABG - coronary artery bypass grafting, MVR - mitral valve repair, IABP - intra-aortic balloon pumping

CABG+MVR patients in the first 3 months and the international normalized ratio (INR) value of 2.0-3.0 was adjusted.

Surgical technique. Standard on-pump surgery was applied to all patients. All severe stenosed coronary vessels of the patients were revascularized using the left internal thoracic artery and saphenous vein graft. Initially, the mitral valve apparatus were examined in detail for valve repair after distal anastomoses were completed. Structural defects of the valve were eliminated using appropriate techniques. Leaflet repair techniques such as triangular resection, quadrangular resection, neochorda and commissurotomy were applied additionally for the structural defects in the valve apparatus (Table 3). Rigid mitral ring (SJMTM Rigid Saddle Ring, St-Jude Medical, St. Paul, MN, USA) was used for all patients with mitral repair. A smaller size of anterior mitral leaflet dimension was used to select the ring measurement. De Vega annuloplasty, or ring annuloplasty was performed with Teflon patch strips applied to tricuspid valves of all patients in both groups who had moderate and severe tricuspid regurgitation. Operative details are given in Table 3.

Statistical analysis. All the data was analyzed using the Statistical Package for Social Sciences version 12.0 (SPSS Inc., Chicago, IL, USA). Data are given as mean ± standard deviation. Numbers and percentages are presented for categorical data. Mann-Whitney test was applied to independent variables. Categorical comparisons were made using the χ² test, or Fisher exact
Results. Demographic characteristics of the patients are shown in Table 1. No significant differences between preoperative demographic characteristics of both groups were observed. In this study, the cause of the tricuspid regurgitation is not searched. Tricuspid valve annuloplasty was carried out in both groups in order to decrease the effect of tricuspid regurgitation to postoperative echocardiographic parameters (Tables 1 & 3). The ring sizes used in patients who had undergone MVR varied between 26 and 34. A 26 number ring was used in 2 patients (4.5%), 28 in 21 (47.7%), 30 in 18 (40.9%), 32 in 2 (4.5%), and 34 in one patient (2.2%). Nine patients in the combined CABG+MVR group and 8 patients in the CABG alone group underwent tricuspid valve annuloplasty. Any significant difference in the tricuspid valve intervention between both groups was not observed \((p=0.3)\). The mean amounts of postoperative drainage in the CABG alone group was 700 cc and in the combined CABG+MVR group was 900 cc. The amount of postoperative blood loss and transfusion of blood products (platelets and fresh frozen plasma) were similar in both groups.

A patient of combined the CABG+MVR group was taken to re-operation for mediastinal bleeding. In the combined CABG+MVR group, operative mortality in the first 30 days was 2.2% with one case (multi-organ failure, which developed due to low cardiac output). In the CABG alone group, the operative mortality was 2.2% with one case of pulmonary infection, which developed as a result of extended intubation and sepsis. One patient (2.2%) from the combined CABG+MVR group had hemiparesis. Two patients of each group with preoperative renal dysfunction were temporarily subjected to hemodialysis. Two died patients who were in the separate groups had hemodialysis during their extended organ failure period in the intensive care and during the sepsis period. Thus, a total of 6 patients (combined CABG+MVR of 6.8%, CABG alone of 6.5%) were subjected to hemodialysis (Table 3).

Although the mean hospitalization period of the patients in the combined CABG+MVR group was longer (8.2 days), it was not statistically significant. The difficulty of dosage for Warfarin treatment applied in the first 3 months necessitated the extended hospitalization period.

The mortality rate for 30 days was 2.2%, and included one case from each group. Within the follow-up period, one patient from the combined CABG+MVR group had exitus due to additional cardiac reasons. One patient had no follow-up due to living out of town. Thus, the number of cases in the combined CABG+MVR group, which was 44 initially decreased by 3 and became 41. In the CABG alone group, the number of cases was 46 in the beginning of the study. In addition to one patient who died in the first 30 days, one patient had exitus due to cardiac and extra cardiac reasons. Two patients of the same group could not be reached, so they did not attend for to follow-up. As a result, 41 patients were followed up in the CABG alone group. Eighty-two patients were followed up until the end of the first year.

There was no significant difference in preoperative variables between both study groups (Table 1). Complete revascularization was performed in both groups. The left internal thoracic artery on the left anterior descending coronary artery as arterial conduit was anastomosed in all patients. The saphenous vein grafts were used in other target coronary vessels. During postoperative evaluations, a statistically significant difference in parameters such as an number of bypass performed \((p=0.7)\), intra-aortic balloon pump (IABP) need \((p=0.2)\), intubation time and hospitalization period \((p=0.2)\) between both groups was not found. The cross clamp period from the combined CABG+MVR group (92±17 min) was longer compared with the CABG group (58±22 min) in terms of statistical significance.

### Table 4 - Preoperative and postoperative one year in the combined CABG+MVR group versus the CABG alone group among 90 patients.

| Variables               | CABG+MVR (n=44) | CABG +MVR (n=41) | Mean change in values | CABG alone (n=46) | CABG alone (n=41) | Mean change in values | P-value |
|-------------------------|-----------------|-----------------|----------------------|-----------------|-----------------|----------------------|---------|
| Regurgitation volume    |                 |                 |                      |                 |                 |                      |         |
| (ml/ beat)             | 34.16±6.52      | 9.4±3.7         | -24.76±19            | 33.6±6.43       | 24.70±9.3       | -8.7±7.2             | 0.001   |
| Vena contracta (mm)    | 4.79±0.73       | 1.39±0.73       | -3.40±0.2            | 4.93±0.77       | 3.48±1.07       | -1.45±0.7            | 0.019   |
| Ejection fraction (%)  | 46.09±7.2       | 47.6±14.3       | +1.51±5.3            | 42.45±6.6       | 43.6±16.4       | +1.15±4.3            | 0.604   |
| LVESVI (ml/m²)         | 75.86±7.8       | 45.09±14.7      | -30.77±25.9          | 75.0±7.6        | 59.4±22.8       | -15.6±9.4            | 0.096   |

Data are express as mean±standard deviation. LVESVI - left ventricular end systolic volume index, CABG - coronary artery bypass grafting, MVR - mitral valve repair.
valve repair, many studies argue that valve repair is not there are numerous studies on this subject asserting has still not been clarified in moderate MR. Although time of CABG. However, the value of mitral valve surgery general agreement for mitral valve repair surgery at the revascularization. In patients with severe MR, there is referred to cardiovascular surgery for coronary artery Discussion. Various levels of MR accompany coronary artery disease in most patients who referred to cardiovascular surgery for coronary artery revascularization. In patients with severe MR, there is general agreement for mitral valve repair surgery at the time of CABG. However, the value of mitral valve surgery has still not been clarified in moderate MR. Although there are numerous studies on this subject asserting valve repair, many studies argue that valve repair is not advantageous. According to the results of our study, MVR was applied on the mitral valves of patients with ischemia-related moderate MR, together with coronary revascularization to eliminate the mechanical problem causing MR although it was regarded as an extra process that extends the pumping period. This situation affected both the clinical results of the patients in the repair group and their echocardiographic evaluation parameters positively.

One of these parameters, LVESVI is accepted as an indicator of left ventricular remodeling and prognosis of ischemic myocardial disease as well. In our study, a statistically significant change was seen in LVESVI, an important indicator of ventricular remodeling of the group who had MVR together with CABG, compared to the group undergoing CABG alone. Furthermore, it was observed in clinical evaluation that the change of effort capacities of the group with mitral annuloplasty was better than that of the other group. Despite the fact that a significant decrease in the regurgitant volume was observed in the combined CABG+MVR group, compared with the CABG alone group, the ejection fraction measured did not create a significant difference between both groups. We considered its reason depend on the regurgitant volume of left atrium is measured as the ejection fraction for calculation system during the ventricular contraction due to the ongoing MR in the CABG alone group. In our study, the cross clamp time of the group who had MVR together with CABG, one of the operative parameters was found to be longer than that of the group who were not subjected to valve intervention. This finding became the single significant value found in the group undergoing CABG alone.

The randomized Ischemic Mitral Evaluation (RIME) trial published by Chan et al. evaluated the measurements of plasma B-type natriuretic peptide (BNP) for prognosis and severity of heart failure, and the use of peak oxygen consumption as an objective measure of the functional capacity. The RIME trial showed significant increase of LVESVI, a decrease of mitral regurgitant volume, a rise of peak oxygen volume, and a fall of BNP level in the combined CABG+MVR group compared with those undergoing CABG alone at one-year follow-up. In the current study, we observed that the clinical results of MVR performed in addition to CABG were much better than those of the patients that underwent CABG alone in the first year. Our results are compatible with the results of RIME trial. Similar to our study, the RIME trial includes only one-year results and this requires the contribution of MVR to patient’s survival, and its results to be revised further over a longer term. Another study that supports our results reported on animal testing using on sheep. In this functional and molecular study, there were 2 groups
moderate MR. Only minor changes of left ventricular volume and left ventricular remodeling were observed in the group that still had MR, whereas an increase in the left ventricular volume and an improvement of the left ventricular remodeling were seen in the group that underwent MVR. In contrast to our study, it was stated in a similar study of Smith et al that MVR of 301 patients who underwent CABG and had moderate MR did not contribute to improvement of left ventricular remodeling positively. In the same study, it was specified that the results of one-year follow-up and clinical evaluations did not show any additional benefit of MVR. Furthermore, it was mentioned that the number of undesired events was higher in the group subjected to MVR.

A Srivastava et al analyzed 16 from 465 studies to find the answer to the question, “Should mitral repair, or mitral replacement be applied to patients with mild, or moderate ischemic MR and underwent CABG?” They concluded that moderate MR in patients undergoing CABG alone negatively affects the survival, and MR did not safely improve after CABG alone. It was stated that the ideas favoring the application of MVR at the same time in patients who underwent CABG and had moderate MR were dominant. Some surgeons recommended concomitant mitral valve surgery with CABG surgery in order to optimize the cardiac function and long-term prognosis of the patients. On the other hand, several surgeons recommended CABG alone as combined CABG+MVR are associated with higher morbidity and mortality.

An important reason for this evaluation is the possibility of MR, which repeats, or creates residue after MVR, and concerns associated with it. Likewise, Dion et al reported in their studies that residue MR of 15% remains after MVR. However, the most important reason for this may be suboptimal surgical techniques, insufficient downsizing of annuloplasty rings, and incomplete revascularization. An important reason for ischemic MR is the posterior papillary muscle dysfunction. In our opinion, important reason of the residue MR can be that adequate emphasis is not placed on the posterior descending artery revascularization or the process is not performed. There are reports on a significant recurrent MR after full-rigid, or semi-rigid ring mitral valve annuloplasty, which usually emerges after 3 years. In our study, recurrent MR occurred in 3 patients (7.3%) within the first follow-up period. The use of three-dimensional rigid annular ring in valve repair may be the reason of this recurrence. According to the 2014 ACC/AHA guidelines, MVR may be considered in patients with chronic moderate secondary MR (stage B) undergoing other cardiac surgery (Class IIb, Level of Evidence: C).

**Study limitations.** One limitation was the lack of assessment of viability of the myocardium. One could argue that the patients offered CABG alone had a significant burden of scar tissue and hence did not show improvement in echocardiographic parameters. Another limitation of the study is the possible impact of inter-observer variation in the interpretation of echocardiograms. The mean follow-up period for their study was one year, so the course of MR of both groups over a longer term.

In conclusions, what is not known moderate MR in patients undergoing CABG affects the outcome adversely and it does not reliably improve after CABG alone. An increase in the effort capacity, improvement of ventricular remodeling, and regression of MR are more significant in patients with combined CABG+MVR compared with those of CABG alone patients. Therefore, patients with ischemic MR should undergo simultaneous MVR at the time of CABG. This positive effect should be supported by longer-term randomized studies.

**References**

1. Lamas GA, Mitchell GF, Flaker GC, Smith SC, Gersh BJ. Clinical significance of MR after acute myocardial infarction. *Circulation* 1997; 96: 827-833.
2. Aronson D, Goldsher N, Zukermann R, Kapeliovich M. Ischemic mitral regurgitation and risk of heart failure after myocardial infarction. *Arch Intern Med* 2006; 166: 2362-2368.
3. Benedetto U, Melina G, Roscitano A, Fiorani B, Capuano F, Scalfani G, et al. Does combined mitral valve surgery improve survival when compared to revascularisation alone in patients with ischemic MR? A meta-analysis on 2479 patients. *J Cardiovasc Med* 2009; 10: 109-114.
4. Akins CW, Hilgenberg AD, Buckley MJ, Vlahakes GJ, Torchiana DF, Daggett WM, et al. Mitral valve reconstruction versus replacement for degenerative or ischemic mitral regurgitation. *Ann Thorac Surg* 1994; 58: 668-676.
5. Duarte IG, Shen Y, MacDonald MJ, Jones EL, Craver JM, Guyton RA. Treatment of moderate mitral regurgitation and coronary disease by coronary bypass alone: late results. *Ann Thorac Surg* 1999; 68: 426-430.
6. Lee R, Li S, Rankin JS, O’Brien SM, Gammie JS, Peterson ED, et al. Society of Thoracic Surgeons Adult Cardiac Surgical Database. Fifteen-year outcome trends for valve surgery in North America. *Ann Thorac Surg* 2011; 91: 677-684.
7. Fattouch K, Guccione F, Sampognaro R, Panzarella G, Corrado E, Navarra E, et al. POINT: Efficacy of adding mitral valve annuloplasty to CABG in patients with moderate ischemic MR: a randomized trial. *J Thorac Cardiovasc Surg* 2009; 138: 278-285.
8. Smith PK, Puskas JD, Ascheim DD, Voisine P, Gelijns AC, Moskowitz AJ, et al. For the Cardiiothoracic Surgical Trials Network Investigators. Surgical treatment of moderate ischemic mitral regurgitation. *N Engl J Med* 2014; 371: 2178-2188.
9. Chan KM, Punjabi PP, Flather M, Wage R, Symmonds K, Roussin I, et al. RIME Investigators. Coronary artery bypass surgery with or without mitral valve annuloplasty in moderate functional ischemic mitral regurgitation: final results of the Randomized Ischemic Mitral Evaluation (RIME) trial. *Circulation* 2012; 126: 2502-2510.

10. Michler RE, Rouleau JL, Al-Khalidi HR, Bonow RO, Pellikka PA, Pohost GM, et al. STICH Trial Investigators. Insights from the STICH trial: change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction. *J Thorac Cardiovasc Surg* 2013; 146: 1139-1145.e6.

11. Beeri R, Yosefy C, Guerrero L, Abedat S, Handschumacher MD, Stroud RE, et al. Early repair of moderate ischemic MR reverses LV remodeling: a functional and molecular study. *Circulation* 2007; 116: I-288-I-293.

12. Srivastava AR, Banerjee A, Jacob S, Dunning J. Should patients undergoing coronary artery bypass grafting with mild to moderate ischemic mitral regurgitation also undergo mitral valve repair or replacement? *Interact Cardiovasc Thorac Surg* 2007; 6: 538-546.

13. McGee EC, Gillinov AM, Blackstone EH, Rajeswaran J, Cohen G. Recurrent mitral regurgitation after annuloplasty for functional ischemic mitral regurgitation. *J Thorac Cardiovasc Surg* 2004; 128: 916-924.

14. Dion R, Benetis R, Elias B, Guennaoui T, Raphael D, Van Dyck M, et al. Mitral valve procedures in ischemic regurgitation. *J Heart Valve Dis* 1995; 4 (Suppl 2): 124-129.

15. Gelsomino S, Lorusso R, De Cicco G, Caciolli S, et al. Five year echocardiographic results of combined undersized mitral ring annuloplasty and coronary artery bypass grafting for chronic ischaemic mitral regurgitation. *Eur Heart J* 2008; 29: 231-240.

16. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA, et. al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2014; 63: e57-e185.

---

**Withdrawal policy**

By submission, the author grants the journal right of first publication. Therefore, the journal discourages unethical withdrawal of manuscript from the publication process after peer review. The corresponding author should send a formal request signed by all co-authors stating the reason for withdrawing the manuscript. Withdrawal of manuscript is only considered valid when the editor accepts, or approves the reason to withdraw the manuscript from publication. Subsequently, the author must receive a confirmation from the editorial office. Only at that stage, authors are free to submit the manuscript elsewhere.

No response from the authors to all journal communication after review and acceptance is also considered unethical withdrawal. Withdrawn manuscripts noted to have already been submitted or published in another journal will be subjected to sanctions in accordance with the journal policy. The journal will take disciplinary measures for unacceptable withdrawal of manuscripts. An embargo of 5 years will be enforced for the author and their co-authors, and their institute will be notified of this action.